BRAF and cancer: More precisely, class I HDACs (HDAC1-3) and HDAC8 play a crucial role in the prevention of apoptosis in BRAF-mutant cancers, including BRAF inhibitor-resistant cells, which can be targeted by isoenzyme-selective inhibitor molecules.